Moreover, it has been shown that treatment with a sodium-glucose transporter protein 2 (SGLT2) inhibitor gives rise to a drop in the plasma level KIM-1 in CKD G3 (stage 3 of chronic kidney disease) patients [19]. Here, SLC5A2 is linked to chronic kidney disease.